Document Type : Original Article(s)
Authors
- Elham Goodarzi 1, 2
- Saeed Rajaei Ramesh 3
- Sajjad Rahimi Pordanjani 4
- Mahshid Abbasi 5
- Fazlollah Fathollahi Shoorabeh 6
1 Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khoram abad, Iran
2 Social Determinants of Health Research Center, Iran University of Medical Sciences, Tehran, Iran
3 Cilinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran
4 Department of Public Health, Behbahan Faculty of Medical Sciences, Behbahan, Iran
5 Department of Radiation Oncology, School of Medicine, Lorestan University of Medical Sciences, Khoram abad, Iran
6 Nutrition Health Research Center, School of Medicine, Lorestan University of Medical Sciences, Khoram abad, Iran
Abstract
Background: Prostate cancer (PC) is the second most common cancer in men and the fifth leading cause of death worldwide. The purpose of this study is to investigate the epidemiological situation concerning the incidence, prevalence, and burden of prostate cancer in Iran from 2009 to 2019.
Methods: The present research is a descriptive-analytical study. To assess the spatial distribution of prostate cancer, data on the incidence, mortality, Disability-adjusted life years (DALY), Years of Life Lost due to premature mortality (YLL), and Years of Life Lost due to disability (YLD) in each province of Iran from 2009 to 2019 were obtained from the Global Burden of Disease (GBD) 2019 website. The incidence and mortality zoning in Iran was mapped using the ArcGIS 10.3 environment. The two-variable Pearson correlation coefficient was used to analyze the data extracted to study the correlation between PC and the Human Development Index.
Results: The highest Age-Standardized Incidence Rate (ASIR) of prostate cancer (40.55 per 100,000), mortality (17.09 per 100,000), YLL (254.1 per 100,000), YLD (23.88 per 100,000), and DALY (277.98 per 100,000) is related to Bushehr province. The results of the Pearson correlation reveal a positive and statistically significant correlation between the ASIR of prostate cancer and the Human Development Index (r=0.651, P=0.0001) in Iran. The highest Percentage of Annual Changes (PAC) in ASIR, Age-Standardized Mortality Rate (ASMR), Age-Standardized Prevalence Rate (ASPR), YLL, YLD, and DALY were related to the provinces of West Azarbayejan (62.9%), Golestan (30.86%), West Azarbayejan (87.66%), Golestan (29.38%), West Azarbayejan (76.95%), and Alborz (31.45%), respectively.
Conclusion: The incidence and mortality rates of prostate cancer in all provinces of the country are on the rise. Therefore, screening programs for early detection to reduce the mortality of the disease, and etiology studies to identify the causes of increased incidence and related factors, can be effective in controlling this cancer in the country.
Keywords
- Moradi A, Zamani M, Moudi E. A systematic review and meta-analysis on incidence of prostate cancer in Iran. Health Promot Perspect. 2019;9:92-8. doi: 10.15171/hpp.2019.13. PubMed PMID: 31249795; PubMed Central PMCID: PMCPMC6588804.
- Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int. 2018;6:41-5. doi: 10.1016/j.prnil.2017.11.003. PubMed PMID: 29922630; PubMed Central PMCID: PMCPMC6004615.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49. doi: 10.3322/caac.21660. PubMed PMID: 33538338.
- Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018;8. doi: 10.1101/cshperspect.a030361. PubMed PMID: 29311132; PubMed Central PMCID: PMCPMC6280714.
- Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015;3:135-40. doi: 10.1016/j.prnil.2015.09.001. PubMed PMID: 26779461; PubMed Central PMCID: PMCPMC4685206.
- Alamgir M. Global And Regional Cancer Epidemiology: According To World Cancer Report 2012 And Others. Journal of Bahria University Medical and Dental College. 2018;8:263-9. doi: 10.51985/JBUMDC2018037.
- Rafiemanesh H, Enayatrad M, Salehiniya H. Epidemiology and trends of mortality from prostate cancer in Iran. Journal of Isfahan Medical School. 2015;33:515-21. [In Persian].
- Murillo-Zamora E, Mendoza-Cano O, Rios-Silva M, Sanchez-Pina RA, Higareda-Almaraz MA, Higareda-Almaraz E, et al. Disability-Adjusted Life Years for Cancer in 2010-2014: A Regional Approach in Mexico. Int J Environ Res Public Health. 2018;15. doi: 10.3390/ijerph15050864. PubMed PMID: 29701664; PubMed Central PMCID: PMCPMC5981903.
- Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, et al. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget. 2017;8:47064-75. doi: 10.18632/oncotarget.16791. PubMed PMID: 28423363; PubMed Central PMCID: PMCPMC5564544.
- Hemminki K, Zhang H, Czene K. Socioeconomic factors in cancer in Sweden. Int J Cancer. 2003;105:692-700. doi: 10.1002/ijc.11150. PubMed PMID: 12740920.
- Wang M, Wasserman E, Geyer N, Carroll RM, Zhao S, Zhang L, et al. Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014. BMC Cancer. 2020;20:394. doi: 10.1186/s12885-020-06902-5. PubMed PMID: 32375682; PubMed Central PMCID: PMCPMC7203834.
- Fidler MM, Bray F, Soerjomataram I. The global cancer burden and human development: A review. Scand J Public Health. 2018;46:27-36. doi: 10.1177/1403494817715400. PubMed PMID: 28669281.
- Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790-801. doi: 10.1016/S1470-2045(12)70211-5. PubMed PMID: 22658655.
- Collaborators GBDRF. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223-49. doi: 10.1016/S0140-6736(20)30752-2. PubMed PMID: 33069327; PubMed Central PMCID: PMCPMC7566194.
- Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-22. doi: 10.1016/S0140-6736(20)30925-9. PubMed PMID: 33069326; PubMed Central PMCID: PMCPMC7567026.
- Roser M, Ritchie H, Spooner F. Burden of disease. Our world in data. 2021.
- DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1859-922. doi: 10.1016/S0140-6736(18)32335-3. PubMed PMID: 30415748; PubMed Central PMCID: PMCPMC6252083.
- Khazaei Z, Sohrabivafa M, Momenabadi V, Moayed L, Goodarzi E. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide prostate cancers and their relationship with the human development index. Advances in Human Biology. 2019;9:245-50. doi: 10.4103/2321-8568.262891.
- Ranis G, Stewart F, Samman E. Human development: beyond the human development index. Journal of Human Development. 2006;7:323-58. doi: 10.1080/14649880600815917.
- Sleeter R, Gould M. Geographic Information System Software to Remodel Population Data Using Dasymetric Mapping Methods; US Department of the Interior. US Geological Survey. 2007. doi: 10.3133/tm11C2.
- Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556-63. doi: 10.1093/annonc/mdn642. PubMed PMID: 19073863.
- Moradi S, Moradi G, Piroozi B, Ghaderi E, Roshani D, Azadnia A. The Burden of Cancer in a Sample of Iranian Population. Iran J Public Health. 2021;50:1687-96. doi: 10.18502/ijph.v50i8.6816. PubMed PMID: 34917540; PubMed Central PMCID: PMCPMC8643534.
- Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S, Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016;4:118-24. doi: 10.1016/j.prnil.2016.07.001. PubMed PMID: 27689070; PubMed Central PMCID: PMCPMC5031898.
- Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10:63-89. doi: 10.14740/wjon1191. PubMed PMID: 31068988; PubMed Central PMCID: PMCPMC6497009.
- Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol. 2021;4:877-92. doi: 10.1016/j.euo.2021.09.006. PubMed PMID: 34716119.
- Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508-47. doi: 10.1016/j.eururo.2020.01.012. PubMed PMID: 32001144.
- Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, Staging and Management of Prostate Cancer. Med Sci (Basel). 2020;8. doi: 10.3390/medsci8030028. PubMed PMID: 32698438; PubMed Central PMCID: PMCPMC7565452.
- Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123:421-9. doi: 10.1002/ijc.23520. PubMed PMID: 18452171.
)